TY - JOUR
T1 - Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson's disease
AU - Rosa, Alexandra I
AU - Fonseca, Inês
AU - Nunes, Maria João
AU - Moreira, Sara
AU - Rodrigues, Elsa
AU - Carvalho, Andreia Neves
AU - Rodrigues, Cecília M P
AU - Gama, Maria João
AU - Castro-Caldas, Margarida
N1 - This work was supported by Fundacdo para a Ciencia e a Tecnologia (FCT), Portugal [grant numbers PTDC/NEU-NMC/0248/2012 (to M.C.C.), UID/DTP/04138/2013 (iMed.ULisboa), and post-doctoral fellowships SFRH/BPD72891/2010 (to A.I.R.), SFRH/BPD/95855/2013 (to M.J.N.) and SFRH/BPD/98023/2013 (to A.N.C.)].
PY - 2017/9
Y1 - 2017/9
N2 - Impaired mitochondrial function and generation of reactive oxygen species are deeply implicated in Parkinson's disease progression. Indeed, mutations in genes that affect mitochondrial function account for most of the familial cases of the disease, and postmortem studies in sporadic PD patients brains revealed increased signs of oxidative stress. Moreover, exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a mitochondrial complex I inhibitor, leads to clinical symptoms similar to sporadic PD. The bile acid tauroursodeoxycholic acid (TUDCA) is an anti-apoptotic molecule shown to protect against MPTP-induced neurodegeneration in mice, but the mechanisms involved are still incompletely identified. Herein we used MPTP-treated mice, as well as primary cultures of mice cortical neurons and SH-SY5Y cells treated with MPP(+) to investigate the modulation of mitochondrial dysfunction by TUDCA in PD models. We show that TUDCA exerts its neuroprotective role in a parkin-dependent manner. Overall, our results point to the pharmacological up-regulation of mitochondrial turnover by TUDCA as a novel neuroprotective mechanism of this molecule, and contribute to the validation of TUDCA clinical application in PD.
AB - Impaired mitochondrial function and generation of reactive oxygen species are deeply implicated in Parkinson's disease progression. Indeed, mutations in genes that affect mitochondrial function account for most of the familial cases of the disease, and postmortem studies in sporadic PD patients brains revealed increased signs of oxidative stress. Moreover, exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a mitochondrial complex I inhibitor, leads to clinical symptoms similar to sporadic PD. The bile acid tauroursodeoxycholic acid (TUDCA) is an anti-apoptotic molecule shown to protect against MPTP-induced neurodegeneration in mice, but the mechanisms involved are still incompletely identified. Herein we used MPTP-treated mice, as well as primary cultures of mice cortical neurons and SH-SY5Y cells treated with MPP(+) to investigate the modulation of mitochondrial dysfunction by TUDCA in PD models. We show that TUDCA exerts its neuroprotective role in a parkin-dependent manner. Overall, our results point to the pharmacological up-regulation of mitochondrial turnover by TUDCA as a novel neuroprotective mechanism of this molecule, and contribute to the validation of TUDCA clinical application in PD.
KW - TUDCA
KW - Parkinson's disease
KW - Oxidative stress
KW - Mitochondria
KW - Mitophagy
KW - Parkin
U2 - 10.1016/j.bbadis.2017.06.004
DO - 10.1016/j.bbadis.2017.06.004
M3 - Article
C2 - 28583715
VL - 1863
SP - 2171
EP - 2181
JO - Biochimica Et Biophysica Acta
JF - Biochimica Et Biophysica Acta
SN - 0006-3002
IS - 9
ER -